株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大鵬薬品工業 - 製品パイプライン分析

Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 240941
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
大鵬薬品工業 - 製品パイプライン分析 Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
出版日: 2016年09月30日 ページ情報: 英文 68 Pages
概要

大鵬薬品工業は日本に本社を置く製薬企業で、アレルギー、免疫系疾患、癌、泌尿器疾患の領域に対する医薬品、抗アレルギー剤、抗がん剤、H2受容体アンタゴニストなどの製品を取り扱っています。

当レポートでは、大鵬薬品工業における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

大鵬薬品工業 の基本情報

  • 大鵬薬品工業 の概要
  • 主要情報
  • 企業情報

大鵬薬品工業 :R&Dの概要

  • 主な治療範囲

大鵬薬品工業 :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

大鵬薬品工業 :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

大鵬薬品工業 :薬剤プロファイル

  • (tegafur + gimeracil + oteracil + calcium folinate)
  • (tegafur + gimeracil + oteracil)
  • bilastine
  • TAS-120
  • TAS-114
  • TAS-115
  • TAS-116
  • TAS-117
  • TAS-119
  • TAS-121
  • TAS-205
  • TAS-2913
  • TAS-2985
  • TAS-5567
  • Small Molecules to Inhibit S100B-p53 Interaction for Cancer

大鵬薬品工業 :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

大鵬薬品工業 :最新のパイプライン情報

大鵬薬品工業 :開発休止中のプロジェクト

大鵬薬品工業 :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

大鵬薬品工業 :企業理念

大鵬薬品工業 :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08150CDB

Summary

Global Markets Direct's, 'Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Taiho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Taiho Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Taiho Pharmaceutical Co., Ltd.
  • The report provides overview of Taiho Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Taiho Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Taiho Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Taiho Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Taiho Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Taiho Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Taiho Pharmaceutical Co., Ltd. Snapshot
    • Taiho Pharmaceutical Co., Ltd. Overview
    • Key Facts
  • Taiho Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Taiho Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Taiho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Taiho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Taiho Pharmaceutical Co., Ltd. - Drug Profiles
    • (calcium folinate + gimeracil + oteracil + tegafur) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (gimeracil + oteracil + tegafur) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (tipiracil hydrochloride + trifluridine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netupitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-116 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-119 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-3681 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-5567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trabectedin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Taiho Pharmaceutical Co., Ltd. - Dormant Projects
  • Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (gimeracil + oteracil + tegafur)
      • (tipiracil hydrochloride + trifluridine)
      • orantinib
      • suplatast tosilate
  • Taiho Pharmaceutical Co., Ltd. - Company Statement
  • Taiho Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Taiho Pharmaceutical Co., Ltd., Key Facts
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pre-Registration, 2016
  • Taiho Pharmaceutical Co., Ltd. - Phase III, 2016
  • Taiho Pharmaceutical Co., Ltd. - Phase II, 2016
  • Taiho Pharmaceutical Co., Ltd. - Phase I, 2016
  • Taiho Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016
  • Taiho Pharmaceutical Co., Ltd. - Preclinical, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
  • Taiho Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top